Many conventional automatic drug delivery systems are well known, including, for example, wearable drug delivery devices of the type shown in
Drug delivery device 102 typically includes a positive displacement pump mechanism. Typically, the pump mechanism comprises a reservoir that stores the liquid drug. The liquid drug stored in the reservoir may be delivered to the user by expelling the drug from a reservoir using a driven plunger that longitudinally translates through the reservoir to force the liquid drug through a fluid port defined in the reservoir. The plunger may be longitudinally translated through the reservoir by, for example, a rigid leadscrew which pushes the plunger forward during pumping. When the reservoir is filled, the leadscrew travels backwards with the plunger. The leadscrew extends past the back of the plunger a distance equal to the stroke of the plunger plus an additional amount to allow for engagement with the drive mechanism. This leads to a space efficiency constraint when scaling the design. If the stroke of the plunger increases, the length of the leadscrew must increase by the same amount.
In wearable, on-body devices, it is desirable to keep the pump mechanism, as well as the overall drug delivery device 102, as small as possible to minimize the impact to the wearer. Additionally, because such drug delivery devices are typically powered by an on-board battery, it is desirable to minimize the power required to operate the device.
Therefore, it would be desirable to replace the prior art pump mechanism with a positive displacement pump having a more space-efficient pumping mechanism to allow for a smaller device, which would decrease the burden on the user.
As used herein, the term “liquid drug” should be interpreted to include any drug in liquid form capable of being administered by a drug delivery device via a subcutaneous cannula, including, for example, insulin, GLP-1, pramlintide, morphine, blood pressure medicines, chemotherapy drugs, fertility drugs, or the like, or co-formulations of two or more of GLP-1, pramlintide, and insulin.
This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended as an aid in determining the scope of the claimed subject matter.
A primary embodiment of the invention disclosed herein uses a double reservoir configuration having a larger, outer reservoir and a smaller, inner reservoir wherein the inner reservoir has a cross-sectional shape slightly smaller than the outer reservoir such that the inner reservoir can linearly translate through the outer reservoir, acting as a plunger for the outer reservoir. The two reservoirs are in fluid communication with each other via a rigid hollow rod which is disposed between the inner and outer reservoirs and which supports a static plunger for the inner reservoir such that, as the inner reservoir is linearly translated into the outer reservoir, the inner reservoir forces a fluid from the outer reservoir, through the hollow rod and into the inner reservoir. The static plunger in the inner reservoir acts to force fluid from the inner reservoir through an outlet fluid port as the inner reservoir is linearly translated into the outer reservoir.
The double reservoir configuration takes advantage of the second reservoir and static plunger to use the space taken by the leadscrew in prior art examples of the drug delivery device. This makes embodiments using the double reservoir configuration more space efficient than prior art examples. Variations of the primary embodiment are directed to various ways of driving the inner reservoir into the outer reservoir and are discussed in detail below.
In the drawings, like reference characters generally refer to the same parts throughout the different views. In the following description, various embodiments of the present invention are described with reference to the following drawings, in which:
This disclosure presents various systems, components and methods for moving a liquid drug from a liquid reservoir in a drug delivery device to a patient interface, such as a needle or cannula. The embodiments described herein provide one or more advantages over conventional, prior art systems, components and methods, namely, a smaller overall footprint of the drug delivery device.
Various embodiments of the present invention include systems and methods for delivering a medication to a user using a drug delivery device (sometimes referred to herein as a “pod”), either autonomously, or in accordance with a wireless signal received from an electronic device. In various embodiments, the electronic device may be a user device comprising a smartphone, a smart watch, a smart necklace, a module attached to the drug delivery device, or any other type or sort of electronic device that may be carried by the user or worn on the body of the user and that executes an algorithm that computes the times and dosages of delivery of the medication.
For example, the user device may execute an “artificial-pancreas” (AP) algorithm that computes the times and dosages of delivery of insulin. The user device may also be in communication with a sensor, such as a glucose sensor or a continuous glucose monitor (CGM), that collects data on a physical attribute or condition of the user, such as a glucose level. The sensor may be disposed in or on the body of the user and may be part of the drug delivery device or may be a separate device.
Alternatively, the drug delivery device may be in communication with the sensor in lieu of or in addition to the communication between the sensor and the user device. The communication may be direct (if, e.g., the sensor is integrated with or otherwise a part of the drug delivery device) or remote/wireless (if, e.g., the sensor is disposed in a different housing than the drug delivery device). In these embodiments, the drug delivery device contains computing hardware (e.g., a processor, memory, firmware, etc.) that executes some or all of the algorithm that computes the times and dosages of delivery of the medication.
Drug delivery system 100, in an optional example, may also include an accessory device 106, such as a smartwatch, a personal assistant device, or the like, which may communicate with the other components of system 100 via either a wired or wireless communication links 191-193.
The user device 105 may be a computing device such as a smartphone, a smartwatch, a tablet, a personal diabetes management (PDM) device, a dedicated diabetes therapy management device, or the like. In an example, user device 105 may include a processor 151, device memory 153, a user interface 158, and a communication interface 154. The user device 105 may also contain analog and/or digital circuitry that may be implemented as a processor 151 for executing processes based on programming code stored in device memory 153, such as user application 160 to manage a user’s blood glucose levels and for controlling the delivery of the drug, medication, or therapeutic agent to the user, as well for providing other functions, such as calculating carbohydrate-compensation dosage, a correction bolus dosage and the like as discussed below. The user device 105 may be used to activate, deactivate, trigger a needle/canula insertion, program, adjust settings, and/or control operation of drug delivery device 102 and/or the analyte sensor 103 as well as the optional smart accessory device 106.
The processor 151 may also be configured to execute programming code stored in device memory 153, such as the user app 160. The user app 160 may be a computer application that is operable to deliver a drug based on information received from the analyte sensor 103, the cloud-based services 111 and/or the user device 105 or optional accessory device 106. The memory 153 may also store programming code to, for example, operate the user interface 158 (e.g., a touchscreen device, a camera or the like), the communication interface 154 and the like. The processor 151, when executing user app 160, may be configured to implement indications and notifications related to meal ingestion, blood glucose measurements, and the like. The user interface 158 may be under the control of the processor 151 and be configured to present a graphical user interface that enables the input of a meal announcement, adjust setting selections and the like as described herein.
In a specific example, when the user app 160 is an AP application, the processor 151 is also configured to execute a diabetes treatment plan (which may be stored in a memory) that is managed by user app 160. In addition to the functions mentioned above, when user app 160 is an AP application, it may further provide functionality to determine a carbohydrate-compensation dosage, a correction bolus dosage and determine a real-time basal dosage according to a diabetes treatment plan. In addition, as an AP application, user app 160 provides functionality to output signals to the drug delivery device 102 via communications interface 154 to deliver the determined bolus and basal dosages.
The communication interface 154 may include one or more transceivers that operate according to one or more radio-frequency protocols. In one embodiment, the transceivers may comprise a cellular transceiver and a Bluetooth® transceiver. The communication interface 154 may be configured to receive and transmit signals containing information usable by user app 160.
User device 105 may be further provided with one or more output devices 155 which may be, for example, a speaker or a vibration transducer, to provide various signals to the user.
In various exemplary embodiments, drug delivery device 102 may include a reservoir 124 and drive mechanism 125, which are controllable by controller 121, executing a medication delivery algorithm (MDA) 129 stored in memory 123, which may perform some or all of the functions of the AP application described above, such that user device 105 may be unnecessary for drug delivery device 102 to carry out drug delivery and control. Alternatively, controller 121 may act to control reservoir 124 and drive mechanism 125 based on signals received from user app 160 executing on a user device 105 and communicated to drug delivery device 102 via communication link 194. Drive mechanism 125 operates to longitudinally translate a plunger through the reservoir, so as to force the liquid drug through an outlet fluid port to needle / cannula 186.
In an alternate embodiment, drug delivery device 102 may also include an optional second reservoir 124-2 and second drive mechanism 125-2 which enables the independent delivery of two different liquid drugs. As an example, reservoir 124 may be filled with insulin, while reservoir 124-2 may be filled with Pramlintide or GLP-1. In some embodiments, each of reservoirs 124, 124-2 may be configured with a separate drive mechanism 125, 125-2, respectively, which may be separately controllable by controller 121 under the direction of MDA 129. Both reservoirs 124, 124-2 may be connected to a common needle / cannula 186.
Drug delivery device 102 may be optionally configured with a user interface 127 providing a means for receiving input from the user and a means for outputting information to the user. User interface 127 may include, for example, light-emitting diodes, buttons on a housing of drug delivery device 102, a sound transducer, a micro-display, a microphone, an accelerometer for detecting motions of the device or user gestures (e.g., tapping on a housing of the device) or any other type of interface device that is configured to allow a user to enter information and/or allow drug delivery device 102 to output information for presentation to the user (e.g., alarm signals or the like).
Drug delivery device 102 includes a patient interface 186 for interfacing with the user to deliver the liquid drug. Patient interface may be, for example, a needle or cannula for delivering the drug into the body of the user (which may be done subcutaneously, intraperitoneally, or intravenously). Drug delivery device 102 further includes a mechanism for inserting the needle / cannula 186 into the body of the user, which may be integral with or attachable to drug delivery device 102. The insertion mechanism may comprise, in one embodiment, an actuator that inserts the needle / cannula 186 under the skin of the user and thereafter retracts the needle, leaving the cannula in place. The actuator may be triggered by user device 105 or may be a manual firing mechanism comprising springs or other energy storing mechanism, that causes the needle / cannula 186 to penetrate the skin of the user.
In one embodiment, drug delivery device 102 includes a communication interface 126, which may be a transceiver that operates according to one or more radio-frequency protocols, such as Bluetooth®, Wi-Fi, near-field communication, cellular, or the like. The controller 121 may, for example, communicate with user device 105 and an analyte sensor 108 via the communication interface 126.
In some embodiments, drug delivery device 102 may be provided with one or more sensors 184. The sensors 184 may include one or more of a pressure sensor, a power sensor, or the like that are communicatively coupled to the controller 121 and provide various signals. For example, a pressure sensor may be configured to provide an indication of the fluid pressure detected in a fluid pathway between the patient interface 186 and reservoir 124. The pressure sensor may be coupled to or integral with the actuator for inserting the patient interface 186 into the user. In an example, the controller 121 may be operable to determine a rate of drug infusion based on the indication of the fluid pressure. The rate of drug infusion may be compared to an infusion rate threshold, and the comparison result may be usable in determining an amount of insulin onboard (IOB) or a total daily insulin (TDI) amount. In one embodiment, analyte sensor 108 may be integral with drug delivery device 102.
Drug delivery device 102 further includes a power source 128, such as a battery, a piezoelectric device, an energy harvesting device, or the like, for supplying electrical power to controller 121, memory 123, drive mechanisms 125 and/or other components of drug delivery device 102.
Drug delivery device 102 may be configured to perform and execute processes required to deliver doses of the medication to the user without input from the user device 105 or the optional accessory device 106. As explained in more detail, MDA 129 may be operable, for example, to determine an amount of insulin to be delivered, IOB, insulin remaining, and the like and to cause controller 121 to activate drive mechanism 125 to deliver the medication from reservoir 124. MDA 129 may take as input data received from the analyte sensor 108 or from user app 160.
The reservoirs 124, 124-2 may be configured to store drugs, medications or therapeutic agents suitable for automated delivery, such as insulin, Pramlintide, GLP-1, co-formulations of insulin and GLP-1, morphine, blood pressure medicines, chemotherapy drugs, fertility drugs or the like.
Drug delivery device 102 may be a wearable device and may be attached to the body of a user, such as a patient or diabetic, at an attachment location and may deliver any therapeutic agent, including any drug or medicine, such as insulin or the like, to a user at or around the attachment location. A surface of drug delivery device 102 may include an adhesive to facilitate attachment to the skin of a user.
When configured to communicate with an external device, such as the user device 105 or the analyte sensor 108, drug delivery device 102 may receive signals over the wired or wireless link 194 from the user device 105 or from the analyte sensor 108. The controller 121 of drug delivery device 102 may receive and process the signals from the respective external devices as well as implementing delivery of a drug to the user according to a diabetes treatment plan or other drug delivery regimen.
Optional accessory device 107 may be, a wearable smart device, for example, a smart watch (e.g., an Apple Watch®), smart eyeglasses, smart jewelry, a global positioning system-enabled wearable, a wearable fitness device, smart clothing, or the like. Similar to user device 105, the accessory device 107 may also be configured to perform various functions including controlling drug delivery device 102. For example, the accessory device 107 may include a communication interface 174, a processor 171, a user interface 178 and a memory 173. The user interface 178 may be a graphical user interface presented on a touchscreen display of the smart accessory device 107. The memory 173 may store programming code to operate different functions of the smart accessory device 107 as well as an instance of the user app 160, or a pared-down version of user app 160 with reduced functionality. In some instances, accessory device 107 may also include sensors of various types.
The analyte sensor 108 may include a controller 131, a memory 132, a sensing/measuring device 133, an optional user interface 137, a power source/energy harvesting circuitry 134, and a communication interface 135. The analyte sensor 108 may be communicatively coupled to the processor 151 of the management device 105 or controller 121 of drug delivery device 102. The memory 132 may be configured to store information and programming code 136.
The analyte sensor 108 may be configured to detect one or multiple different analytes, such as glucose, lactate, ketones, uric acid, sodium, potassium, alcohol levels or the like, and output results of the detections, such as measurement values or the like. The analyte sensor 108 may, in an exemplary embodiment, be configured as a continuous glucose monitor (CGM) to measure a blood glucose values at a predetermined time interval, such as every 5 minutes, every 1 minute, or the like. The communication interface 135 of analyte sensor 108 may have circuitry that operates as a transceiver for communicating the measured blood glucose values to the user device 105 over a wireless link 195 or with drug delivery device 102 over the wireless communication link 108. While referred to herein as an analyte sensor 108, the sensing/measuring device 133 of the analyte sensor 108 may include one or more additional sensing elements, such as a glucose measurement element, a heart rate monitor, a pressure sensor, or the like. The controller 131 may include discrete, specialized logic and/or components, an application-specific integrated circuit, a microcontroller or processor that executes software instructions, firmware, programming instructions stored in memory (such as memory 132), or any combination thereof.
Similar to the controller 121 of drug delivery device 102, the controller 131 of the analyte sensor 108 may be operable to perform many functions. For example, the controller 131 may be configured by programming code 136 to manage the collection and analysis of data detected by the sensing and measuring device 133.
Although the analyte sensor 108 is depicted in
Drug delivery system 100 may communicate with or receive services from cloud-based services 111. Services provided by cloud-based services 111 may include data storage that stores personal or anonymized data, such as blood glucose measurement values, historical IOB or TDI, prior carbohydrate-compensation dosage, and other forms of data. In addition, the cloud-based services 111 may process anonymized data from multiple users to provide generalized information related to TDI, insulin sensitivity, IOB and the like. The communication link 115 that couples the cloud-based services 111 to the respective devices 102, 105, 106, 108 of system 100 may be a cellular link, a Wi-Fi link, a Bluetooth® link, or a combination thereof.
The wireless communication links 115 and 191-196 may be any type of wireless link operating using known wireless communication standards or proprietary standards. As an example, the wireless communication links 191-196 may provide communication links based on Bluetooth®, Zigbee®, Wi-Fi, a near-field communication standard, a cellular standard, or any other wireless protocol via the respective communication interfaces 126, 135, 154 and 174.
In an operational example, user application 160 implements a graphical user interface that is the primary interface with the user and is used to start and stop drug delivery device 102, program basal and bolus calculator settings for manual mode as well as program settings specific for automated mode (hybrid closed-loop or closed-loop).
User app 160, provides a graphical user interface 158 that allows for the use of large text, graphics, and on-screen instructions to prompt the user through the set-up processes and the use of system 100. It will also be used to program the user’s custom basal insulin delivery profile, check the status, of drug delivery device 102, initiate bolus doses of insulin, make changes to a patient’s insulin delivery profile, handle system alerts and alarms, and allow the user to switch between automated mode and manual mode.
User app 160 may be configured to operate in a manual mode in which user app 160 will deliver insulin at programmed basal rates and user-defined bolus amounts with the option to set temporary basal profiles. The controller 121 will also have the ability to function as a sensor-augmented pump in manual mode, using sensor glucose data provided by the analyte sensor 108 to populate the bolus calculator.
User app 160 may be configured to operate in an automated mode in which user app 160 supports the use of multiple target blood glucose values. For example, in one embodiment, target blood glucose values can range from 110-150 mg/dL, in 10 mg/dL increments, in 5 mg/dL increments, or other increments, but preferably 10 mg/dL increments. The experience for the user will reflect current setup flows whereby the healthcare provider assists the user to program basal rates, glucose targets and bolus calculator settings. These in turn will inform the user app 160 for insulin dosing parameters. The insulin dosing parameters will be adapted over time based on the total daily insulin (TDI) delivered during each use of drug delivery device 102. A temporary hypoglycemia protection mode may be implemented by the user for various time durations in automated mode. With hypoglycemia protection mode, the algorithm reduces insulin delivery and is intended for use over temporary durations when insulin sensitivity is expected to be higher, such as during exercise.
The user app 160 (or MDA 129) may provide periodic insulin micro-boluses based upon past glucose measurements and/or a predicted glucose over a prediction horizon (e.g., 60 minutes). Optimal post-prandial control may require the user to give meal boluses in the same manner as current pump therapy, but normal operation of the user app 160 will compensate for missed meal boluses and mitigate prolonged hyperglycemia. The user app 160 uses a control-to-target strategy that attempts to achieve and maintain a set target glucose value, thereby reducing the duration of prolonged hyperglycemia and hypoglycemia.
In some embodiments, user device 105 and the analyte sensor 108 may not communicate directly with one another. Instead, data (e.g., blood glucose readings) from analyte sensor may be communicated to drug delivery device 102 via link 196 and then relayed to user device 105 via link 194. In some embodiments, to enable communication between analyte sensor 108 and user device 105, the serial number of the analyte sensor must be entered into user app 160.
User app 160 may provide the ability to calculate a suggested bolus dose through the use of a bolus calculator. The bolus calculator is provided as a convenience to the user to aid in determining the suggested bolus dose based on ingested carbohydrates, most-recent blood glucose readings (or a blood glucose reading if using fingerstick), programmable correction factor, insulin to carbohydrate ratio, target glucose value and insulin on board (IOB). IOB is estimated by user app 160 taking into account any manual bolus and insulin delivered by the algorithm.
The primary embodiment of the invention is shown schematically in
Preferably, there is a fluid seal 318 defined around the circumference of an exterior surface of inner reservoir 304 so as to create a fluid seal between the exterior surface of inner reservoir 302 and an interior surface of outer reservoir 304, to prevent any fluid contained within outer reservoir 302 from leaking to the outside. Likewise, static plunger 306 is configured with a fluid seal around an outer circumference thereof to create a seal between plunger 306 and an interior wall of inner reservoir 304, to contain fluid in inner reservoir 304. Additional seals (not shown) may be provided between static plunger 306 and hollow tube 308 to prevent leakage between inner reservoir 304 and outer reservoir 302 and between hollow tube 308 and the end wall of inner reservoir 304, which acts as a plunger as inner reservoir 304 moves in direction “B” into outer reservoir 302.
From the fully filled configuration shown in
The positions of both fluid fill port 312 and fluid outlet port 310 are flexible so as to be able to be located on either of inner reservoir 304 or outer reservoir 302. The option which best fits the system requirements may be chosen for implementation. For example, having the fluid port on the moving, inner reservoir 304 may create challenges around integration of the pumping system with other subsystems of drug delivery device 102. In various embodiments, either of fluid ports 310, 312 may act as an inlet fluid port of an outlet fluid port. In such cases, it may be necessary to seal the fluid port acting as the outlet port during filling of the reservoirs and to seal the fluid port acting as the inlet port during dispending of the fluid. In some embodiments, the pumping mechanism may be configured with only one of fluid ports 310, 312, which acts as both an inlet fluid port and an outlet fluid port.
As explained above, an accurate dispensing of fluid requires an accurately controlled motion of inner reservoir 304 into outer reservoir 302. In some embodiments, a clutch may be provided between the drive mechanism and the reservoir to which the drive mechanism is connected. This allows the drive mechanism to be disengaged from the reservoir to allow the user to fill the reservoir (e.g., wherein the reservoir is required, during the filling process, to move in the opposite direction from its motion during the dispensing process). Once the filling is complete, the clutch may be engaged to connect the drive mechanism to the reservoir and the fluid may thereafter be dispensed through actuation of the drive mechanism. Several variations of the primary embodiment featuring different drive mechanisms will now be disclosed.
Leadscrew 510 may be rotated via any known means. For example, the tube nut 404 shown in
Although the leadscrew / tube nut mechanism shown in the variations of
The use of the dual leadscrews not only increases the energy efficiency of the system by minimizing or eliminating the off-axis moment applied to the leadscrew / tube nut interface but also improves the alignment between inner reservoir 304 and outer reservoir 302. The variation using two leadscrews (or one leadscrew and a smooth cylindrical rod) can be applied to any of the variations of the invention shown in
Exemplary embodiments of the invention disclosed herein have been presented with reservoirs having a circular cross-sectional shape. However, the invention is not intended to be limited thereto. In alternate embodiments, reservoirs having different cross-sectional shapes may be used, examples of which are shown in
As described with respect to the embodiments and variations disclosed herein, some interfaces, such as the interface between inner reservoir 304 and outer reservoir 302 need to be sealed to achieve the expected performance of the pumping mechanism. In these cases, an O-ring may be used, as shown in
The following examples pertain to various embodiments of the systems and methods disclosed herein for implementation of an automatic drug delivery system having a double reservoir pumping mechanism.
Example 1 is a first embodiment of a pumping mechanism comprising an outer reservoir, and inner reservoir, configured to linearly translate into and out of the other reservoir, static plunger disposed on the interior of the inner reservoir, a hollow tube supporting the static plunger fluidly coupling the inner reservoir and the other reservoir, one or more fluid ports and a drive mechanism for linearly translating the inner reservoir into the outer reservoir.
Example 2 is an extension of Example 1, or any other example disclosed herein, further comprising a fluid seal between the inner and outer reservoirs.
Example 3 is an extension of Example 1, or any other example disclosed herein, wherein the other reservoir is rigidly attached to a structure external to the pumping mechanism.
Example 4 is an extension of Example 3, or any other example disclosed herein, wherein the inner reservoir defines a through hole and the drive mechanism comprises a leadscrew engaged with the through hole such that a linear translation of the leadscrew causes a linear translation of the inner reservoir into the outer reservoir.
Example 5 is an extension of Example 4, or any other example disclosed herein, wherein the drive mechanism further comprises a tube nut in threaded engagement with the leadscrew such that a rotation of the tube nut causes the linear translation of the leadscrew.
Example 6 is an extension of Example 1, or any other example disclosed herein, wherein an exterior surface of the inner reservoir defines a depression, the drive mechanism comprising a pusher member defining a through hole having internal threads and a protrusion thereon, and a leadscrew in threaded engagement with the through hole of the pusher member, wherein a rotation of the leadscrew causes a linear translation of the pusher member to engage the protrusion with the depression on the inner reservoir two push the inner reservoir into the outer reservoir.
Example 7 is an extension of Example 6, or any other example disclosed herein, wherein the protrusion is semi-spherical in shape and the depression is concave.
Example 8 is an extension of Example 1, or any other example disclosed herein, wherein the drive mechanism comprises a pusher element integral with the inner reservoir and defining a through hole having internal threads and a leadscrew in threaded engagement with the through hole such that a rotation of leadscrew causes a linear translation of the pusher element and a linear translation of the inner reservoir into the outer reservoir.
Example 9 is an extension of Example 1, or any other example disclosed herein, wherein the drive mechanism comprises a rack gear disposed on the outer surface of the outer reservoir and a pinion gear engaged with the rack gear such that a rotation of the pinion gear causes a linear translation of the outer reservoir toward the end of reservoir.
Example 10 is an extension of Example 7, or any other example disclosed herein, wherein the inner reservoir defines a second through hole disposed on an exterior surface opposite the through hole wherein the drive mechanism further comprises a second leadscrew engaged with the second through hole such that a synchronized linear translation of the leadscrew and the second leadscrew causes a linear translation of the inner reservoir into the outer reservoir.
Example 11 is an extension of Example 8, or any other example disclosed herein, wherein the drive mechanism further comprises a second pusher element integral with the inner reservoir defining a through hole having internal threads and a second leadscrew in threaded engagement with the through hole of the second pusher element wherein a synchronized rotation of the leadscrews causes a linear translation of the inner reservoir into the outer reservoir.
Example 12 is an extension of Example 9, or any other example disclosed herein, wherein the drive mechanism further comprises a second rack gear disposed on an outer surface of the outer reservoir opposite the rack gear and a second pinion gear engaged with the second rack gear such that a synchronized rotation of the pinion gears causes a linear translation of the outer reservoir toward the inner reservoir.
Example 13 is an extension of Example 1, or any other example disclosed herein, wherein the inner reservoir and the outer reservoir have a cross-sectional shape selected from a group consisting of elliptical, flattened circular and rectangular with rounded corners.
Example 14 is an extension of Example 1, or any other example disclosed herein, further comprising a fluid seal disposed on a circumferential surface of the static plunger such as to create a fluid seal between the plunger and an interior surface of the inner reservoir.
Example 15 is an extension of Example 1, or any other example disclosed herein, further comprising a fluid seal between an interior surface of the outer reservoir and an exterior surface of the inner reservoir.
Example 16 is an extension of Example 1, or any other example disclosed herein, further comprising a fluid seal between the hollow tube in the static plunger.
Example 17 a second embodiment of a pumping mechanism comprising an outer reservoir, and inner reservoir configured to linearly translate into and out of the outer reservoir, a static plunger disposed on the interior of the inner reservoir, a leadscrew, disposed internal to the inner reservoir coaxial with the longitudinal axis of the inner reservoir and extending through the static plunger to contact an end wall of the inner reservoir and a tube nut, engaged with the leadscrew such that rotation of the tube nut causes a linear translation of the leadscrew pushing the inner reservoir into the outer reservoir.
Example 18 is an extension of Example 17, or any other example disclosed herein, wherein the outer reservoir is rigidly attached to a structure external to the pumping mechanism.
Example 19 is an extension of Example 18, or any other example disclosed herein, further comprising a hollow tube containing the tube nut, the hollow tube rigidly attached to a structure external to the pumping mechanism and supporting the static plunger.
Example 20 is extension of Example 19, or any other example disclosed herein, further comprising a drive mechanism for rotating the tube nut.
Example 21 is an extension of Example 20, or any other example disclosed herein, further comprising a first fluid port defined in a wall of the outer reservoir and a second fluid port defined in a wall of the inner reservoir.
Example 22 is an extension of Example 21, or any other example disclosed herein, wherein the first fluid port and second fluid port are fluidly coupled external to the pumping mechanism.
Example 23 is an extension of Example 17, or any other example disclosed herein, further comprising a fluid seal disposed on a circumferential surface of the static plunger such as to create a fluid seal between the plunger and an interior surface of the inner reservoir.
Example 24 is an extension of example 17, or any other example disclosed herein, further comprising a fluid seal between the inner reservoir and the outer reservoir.
Example 25 is an extension of example 17, or any other example disclosed herein, wherein the inner reservoir and the outer reservoir have a cross-sectional shape selected from a group consisting of elliptical, flattened circular and rectangular with rounded corners.
Example 26 is a third embodiment of a pumping mechanism comprising an outer reservoir, an inner reservoir configured to linearly translate into the outer reservoir and a drive mechanism for linearly translating the inner reservoir, wherein a portion of the inner reservoir acts as a plunger within the outer reservoir to force medication contained in the outer reservoir through a first fluid port.
Software related implementations of the techniques described herein may include, but are not limited to, firmware, application specific software, or any other type of computer readable instructions that may be executed by one or more processors. The computer readable instructions may be provided via non-transitory computer-readable media. Hardware related implementations of the techniques described herein may include, but are not limited to, integrated circuits (ICs), application specific ICs (ASICs), field programmable arrays (FPGAs), and/or programmable logic devices (PLDs). In some examples, the techniques described herein, and/or any system or constituent component described herein may be implemented with a processor executing computer readable instructions stored on one or more memory components.
To those skilled in the art to which the invention relates, many modifications and adaptations of the invention may be realized. Implementations provided herein, including sizes, shapes, ratings compositions and specifications of various components or arrangements of components, and descriptions of specific manufacturing processes, should be considered exemplary only and are not meant to limit the invention in any way. As one of skill in the art would realize, many variations on implementations discussed herein which fall within the scope of the invention are possible. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. Accordingly, the method and apparatus disclosed herein are not to be taken as limitations on the invention but as an illustration thereof. The scope of the invention is defined by the claims which follow.
This application claims the benefit of U.S. Provisional Pat. Application No. 63/304,270, filed Jan. 28, 2022, the contents of which are incorporated herein by reference in their entirety.
Number | Date | Country | |
---|---|---|---|
63304270 | Jan 2022 | US |